24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

Authors
Publication date
1 January 2012
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Supporting member

    Oxford University Research Archive

    redirect
    oaioai:ora.ox.ac.uk:uuid:43610c22...
    Last time updated on 30/09/2015

    Oxford University Research Archive (ORA)

    redirect
    Last time updated on 18/04/2020